Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
C. Boutros(Institut Gustave Roussy), Caroline Robert(Institut Gustave Roussy), Jean‐Charles Soria(Inserm), Franck Carbonnel(Université Paris-Saclay), Émilie Lanoy(Université Paris-Sud), Émilie Routier(Université Paris-Saclay), Matthieu Texier(Institut Gustave Roussy), Alexander M.M. Eggermont(University Medical Center Utrecht), C. Libenciuc(Institut Gustave Roussy), Stéphane Champiat(The University of Texas MD Anderson Cancer Center), Aurélien Marabelle(Institut Gustave Roussy), Armandine Berdelou(Institut Gustave Roussy), Hassane Izzeddine(Sorbonne Université), Olivier Lambotte(Inserm), Christine Mateus(Centre National de la Recherche Scientifique), François Leroy Ladurie(Centre Chirurgical Marie Lannelongue), Ahmad A. Tarhini(UPMC Hillman Cancer Center)
Cited by 1,112
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k